The Never-Ending Story of Complicated Hypertension

1 Gutierrez JA, Aday AW, Patel MR, Jones WS. Polyvascular disease. Circulation: Cardiovascular Interventions. 2019; 12(12): e007385. doi:10.1161/CIRCINTERVENTIONS.119.007385. GutierrezJA AdayAW PatelMR JonesWS Polyvascular disease Circulation: Cardiovascular Interventions 2019 12 12 e007385 10.1161/CIRCINTERVENTIONS.119.007385 766052631833412 Open DOISearch in Google Scholar

2 Weissler EH, Jones WS, Desormais I, et al. Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. Atherosclerosis. 2020; 315: 10–17. doi:10.1016/j.atherosclerosis.2020.11.001. WeisslerEH JonesWS DesormaisI Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy Atherosclerosis 2020 315 10 17 10.1016/j.atherosclerosis.2020.11.001 33190107 Open DOISearch in Google Scholar

3 Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the american heart association. Hypertension. 2018; 72(5): e53–e90. doi:10.1161/HYP.0000000000000084. CareyRM CalhounDA BakrisGL Resistant hypertension: detection, evaluation, and management: a scientific statement from the american heart association Hypertension 2018 72 5 e53 e90 10.1161/HYP.0000000000000084 653099030354828 Open DOISearch in Google Scholar

4 Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018; 39(33): 3021–3104. doi:10.1093/eurheartj/ehy339. WilliamsB ManciaG SpieringW 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) European Heart Journal 2018 39 33 3021 3104 10.1093/eurheartj/ehy339 30165516 Open DOISearch in Google Scholar

5 Oliveras A, de la Sierra A. Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes. J Hum Hypertens. 2014; 28(4): 213–217. doi:10.1038/jhh.2013.77. OliverasA de la SierraA Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes J Hum Hypertens 2014 28 4 213 217 10.1038/jhh.2013.77 23985879 Open DOISearch in Google Scholar

6 Liang S, Zhang XG, Cai GY, et al. Identifying parameters to distinguish non-diabetic renal diseases from diabetic nephropathy in patients with type 2 diabetes mellitus: a meta-analysis. PLOS ONE. 2013; 8(5): e64184. doi:10.1371/journal.pone.0064184. LiangS ZhangXG CaiGY Identifying parameters to distinguish non-diabetic renal diseases from diabetic nephropathy in patients with type 2 diabetes mellitus: a meta-analysis PLOS ONE 2013 8 5 e64184 10.1371/journal.pone.0064184 365387823691167 Open DOISearch in Google Scholar

7 Groenland EH, Bots ML, Asselbergs FW, et al. Apparent resistant hypertension and the risk of recurrent cardiovascular events and mortality after a first manifestation of vascular disease. European Heart Journal. 2020; 41(Supplement_2): ehaa946.2733. doi:10.1093/ehjci/ehaa946.2733. GroenlandEH BotsML AsselbergsFW Apparent resistant hypertension and the risk of recurrent cardiovascular events and mortality after a first manifestation of vascular disease European Heart Journal 2020 41 Supplement_2 ehaa946.2733. 10.1093/ehjci/ehaa946.2733 Open DOISearch in Google Scholar

8 Venkataraman S, Vungarala S, Covassin N, Somers VK. Sleep Apnea, Hypertension and the sympathetic nervous system in the adult population. J Clin Med. 2020; 9(2): 591. doi:10.3390/jcm9020591. VenkataramanS VungaralaS CovassinN SomersVK Sleep Apnea, Hypertension and the sympathetic nervous system in the adult population J Clin Med 2020 9 2 591 10.3390/jcm9020591 707361832098169 Open DOISearch in Google Scholar

9 Parati G, Ochoa JE, Bilo G, et al. Obstructive sleep apnea syndrome as a cause of resistant hypertension. Hypertens Res. 2014; 37(7): 601–613. doi:10.1038/hr.2014.80. ParatiG OchoaJE BiloG Obstructive sleep apnea syndrome as a cause of resistant hypertension Hypertens Res 2014 37 7 601 613 10.1038/hr.2014.80 24804613 Open DOISearch in Google Scholar

10 Martínez-García MA, Capote F, Campos-Rodríguez F, et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA. 2013; 310(22): 2407–2415. doi:10.1001/jama.2013.281250. Martínez-GarcíaMA CapoteF Campos-RodríguezF Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial JAMA 2013 310 22 2407 2415 10.1001/jama.2013.281250 24327037 Open DOISearch in Google Scholar

11 Ruzicka M, Knoll G, Leenen FHH, Leech J, Aaron SD, Hiremath S. Effects of CPAP on blood pressure and sympathetic activity in patients with diabetes mellitus, chronic kidney disease, and resistant hypertension. CJC Open. 2020; 2(4): 258–264. doi:10.1016/j.cjco.2020.03.010. RuzickaM KnollG LeenenFHH LeechJ AaronSD HiremathS Effects of CPAP on blood pressure and sympathetic activity in patients with diabetes mellitus, chronic kidney disease, and resistant hypertension CJC Open 2020 2 4 258 264 10.1016/j.cjco.2020.03.010 736581532695977 Open DOISearch in Google Scholar

12 Labarca G, Dreyse J, Drake L, Jorquera J, Barbe F. Efficacy of continuous positive airway pressure (CPAP) in the prevention of cardiovascular events in patients with obstructive sleep apnea: Systematic review and meta-analysis. Sleep Med Rev. 2020; 52: 101312. doi:10.1016/j.smrv.2020.101312. LabarcaG DreyseJ DrakeL JorqueraJ BarbeF Efficacy of continuous positive airway pressure (CPAP) in the prevention of cardiovascular events in patients with obstructive sleep apnea: Systematic review and meta-analysis Sleep Med Rev 2020 52 101312. 10.1016/j.smrv.2020.101312 32248026 Open DOISearch in Google Scholar

13 Gordon A, Wu S, Munns N, DeVries A, Power T. Untreated sleep apnea: an analysis of administrative data to identify risk factors for early nonadherence. J Clini Sleep Med. 2018; 14(08): 1303–1313. doi:10.5664/jcsm.7260. GordonA WuS MunnsN DeVriesA PowerT Untreated sleep apnea: an analysis of administrative data to identify risk factors for early nonadherence J Clini Sleep Med 2018 14 08 1303 1313 10.5664/jcsm.7260 608694130092889 Open DOISearch in Google Scholar

14 Prince M, Tafur JD, White CJ. When and how should we revascularize patients with atherosclerotic renal artery stenosis? JACC: Cardiovascular Interventions. 2019; 12(6): 505–517. doi:10.1016/j.jcin.2018.10.023. PrinceM TafurJD WhiteCJ When and how should we revascularize patients with atherosclerotic renal artery stenosis? JACC: Cardiovascular Interventions 2019 12 6 505 517 10.1016/j.jcin.2018.10.023 30898248 Open DOISearch in Google Scholar

15 Alsaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol. 2007; 60(1): 18–26. doi:10.1136/jcp.2005.035592. AlsaadKO HerzenbergAM Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update J Clin Pathol 2007 60 1 18 26 10.1136/jcp.2005.035592 186060817213346 Open DOISearch in Google Scholar

16 Hamrahian SM, Falkner B. Hypertension in chronic kidney disease. Adv Exp Med Biol. 2017; 956: 307–325. doi:10.1007/5584_2016_84. HamrahianSM FalknerB Hypertension in chronic kidney disease Adv Exp Med Biol 2017 956 307 325 10.1007/5584_2016_84 27873228 Open DOISearch in Google Scholar

17 Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019; 26(6): 2065–2123. doi:10.1007/s12350-019-01760-6. DorbalaS AndoY BokhariS ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging J Nucl Cardiol 2019 26 6 2065 2123 10.1007/s12350-019-01760-6 31468376 Open DOISearch in Google Scholar

18 Palma JA, Gonzalez-Duarte A, Kaufmann H. Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management. Clin Auton Res. 2019; 29(Suppl 1): 33–44. doi:10.1007/s10286-019-00623-x. PalmaJA Gonzalez-DuarteA KaufmannH Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management Clin Auton Res 2019 29 Suppl 1 33 44 10.1007/s10286-019-00623-x 676350931452021 Open DOISearch in Google Scholar

19 Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med. 1998; 338(17):1202–1211. doi:10.1056/NEJM199804233381707. OrthSR RitzE The nephrotic syndrome N Engl J Med 1998 338 17 1202 1211 10.1056/NEJM199804233381707 9554862 Open DOISearch in Google Scholar

20 Krummel T, Bazin D, Faller AL, Hannedouche T. [Hypertensive nephrosclerosis]. Presse Med. 2012; 41(2):116–124. doi:10.1016/j.lpm.2011.04.008. KrummelT BazinD FallerAL HannedoucheT [Hypertensive nephrosclerosis] Presse Med 2012 41 2 116 124 10.1016/j.lpm.2011.04.008 21641755 Open DOISearch in Google Scholar

21 Chertow GM, Normand SLT, McNeil BJ. “Renalism”: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am Soc Nephrol. 2004; 15(9): 2462–2468. doi:10.1097/01.ASN.0000135969.33773.0B. ChertowGM NormandSLT McNeilBJ “Renalism”: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency J Am Soc Nephrol 2004 15 9 2462 2468 10.1097/01.ASN.0000135969.33773.0B Open DOISearch in Google Scholar

22 Gutierrez JA, Aday AW, Patel MR, Jones WS. Polyvascular disease: reappraisal of the current clinical landscape. Circ Cardiovasc Interv. 2019; 12(12): e007385. doi:10.1161/CIRCINTERVENTIONS.119.007385. GutierrezJA AdayAW PatelMR JonesWS Polyvascular disease: reappraisal of the current clinical landscape Circ Cardiovasc Interv 2019 12 12 e007385 10.1161/CIRCINTERVENTIONS.119.007385 Open DOISearch in Google Scholar

23 ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography. Circulation. 2011; 124(11): 1250–1259. doi:10.1161/CIRCULATIONAHA.111.038943. ACT Investigators Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography Circulation 2011 124 11 1250 1259 10.1161/CIRCULATIONAHA.111.038943 Open DOISearch in Google Scholar

24 Giacoppo D, Gargiulo G, Buccheri S, et al. Preventive strategies for contrast-induced acute kidney injury in patients undergoing percutaneous coronary procedures: evidence from a hierarchical bayesian network meta-analysis of 124 trials and 28 240 patients. Circ Cardiovasc Interv. 2017; 10(5): e004383. doi:10.1161/CIRCINTERVENTIONS.116.004383. GiacoppoD GargiuloG BuccheriS Preventive strategies for contrast-induced acute kidney injury in patients undergoing percutaneous coronary procedures: evidence from a hierarchical bayesian network meta-analysis of 124 trials and 28 240 patients Circ Cardiovasc Interv 2017 10 5 e004383 10.1161/CIRCINTERVENTIONS.116.004383 Open DOISearch in Google Scholar

25 KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International. 2013; 3. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease Kidney International 2013 3 Search in Google Scholar

26 Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017; 389(10076): 1312–1322. doi:10.1016/S0140-6736(17)30057-0. NijssenEC RennenbergRJ NelemansPJ Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial Lancet 2017 389 10076 1312 1322 10.1016/S0140-6736(17)30057-0 Open DOISearch in Google Scholar

27 Authors/Task Force Members, Kristensen SD, Knuuti J, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). European Heart Journal. 2014; 35(35): 2383–2431. doi:10.1093/eurheartj/ehu282. Authors/Task Force Members KristensenSD KnuutiJ 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA) European Heart Journal 2014 35 35 2383 2431 10.1093/eurheartj/ehu282 25086026 Open DOISearch in Google Scholar